LJ-2698

a highly potent human A3 adenosine receptor antagonist

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Wounds and Injuries (Trauma) 01/01/2018 - "LJ-2698 effectively prevented kidney injuries such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, inflammation, and oxidative stress in diabetic mice as much as losartan. "
2.	Pulmonary Emphysema 05/01/2020 - "LJ-2698, an Adenosine A3 Receptor Antagonist, Alleviates Elastase-Induced Pulmonary Emphysema in Mice."
3.	Inflammation (Inflammations) 01/01/2018 - "LJ-2698 effectively prevented kidney injuries such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, inflammation, and oxidative stress in diabetic mice as much as losartan. "
4.	Hypertrophy 01/01/2018 - "LJ-2698 effectively prevented kidney injuries such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, inflammation, and oxidative stress in diabetic mice as much as losartan. "
5.	Fibrosis (Cirrhosis) 01/01/2018 - "LJ-2698 effectively prevented kidney injuries such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, inflammation, and oxidative stress in diabetic mice as much as losartan. "

1.	Adenosine A3 Receptor
2.	Losartan (Cozaar)
3.	Pancreatic Elastase (Elastase)